Abstract
Chronic lymphocytic leukemia (CLL) is a disease of the lymphoid system, in which the most common therapy is fludarabine plus cyclophosphamide (FC). The addition of rituximab to FC has been used, a combination known as FCR. To perform a systematic review with meta-analysis of clinical trials between 2000 and 2012 comparing FC and FCR in patients with CLL. Electronic databases were searched using keywords related to the objectives of this review. The outcomes examined were progression-free survival and complete remission. The progression-free survival and the overall survival showed significant difference between the two regimens, with complete remission being more frequent in FCR-treated patients (odds ratio=2.58; 95% CI: 2.13-3.13). Patients treated with FCR showed significantly higher neutropenia and serious adverse reactions. Despite the favorable results of the FCR regimen on outcomes including complete remission, progression-free survival, and overall survival, there is a lack of methodological rigor and appropriate analyses in many of these studies, and thus, there is a need for further studies examining the effect of rituximab in CLL patients.
References
Feb 1, 1996·Controlled Clinical Trials·A R JadadH J McQuay
May 26, 1999·Journal of the National Cancer Institute
Dec 10, 1999·Lancet·D MoherD F Stroup
Apr 17, 2001·Annals of Internal Medicine·D G AltmanUNKNOWN CONSORT GROUP (Consolidated Standards of Reporting Trials)
Jan 17, 2004·Blood·Gerard LozanskiJohn C Byrd
Dec 15, 2005·Cancer·William WierdaMichael Keating
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael R GreverJohn C Byrd
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnMartin S Tallman
Apr 26, 2008·BMJ : British Medical Journal·Gordon H GuyattUNKNOWN GRADE Working Group
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tadeusz RobakSergey I Moiseev
Jul 14, 2010·Best Practice & Research. Clinical Haematology·Michael Hallek
Oct 5, 2010·Lancet·M HallekUNKNOWN German Chronic Lymphocytic Leukaemia Study Group
Jan 8, 2011·The Oncologist·Sandra J CasakRichard Pazdur
Sep 21, 2011·Expert Review of Anticancer Therapy·Stefano Molica
Mar 1, 2012·Expert Opinion on Biological Therapy·Tadeusz Robak
Mar 13, 2012·Cancer Treatment Reviews·Mindy M ChengEmily Beth Devine
Jun 19, 2012·Cancer Treatment Reviews·Teruhiko TerasawaThomas A Trikalinos
Jul 12, 2012·Expert Review of Hematology·Maria Teresa Scupoli, Giovanni Pizzolo
Jul 21, 2012·Leukemia·M C Di BernardoR S Houlston
Feb 5, 2013·The Journal of Rheumatology·Emilio Besada, Johannes C Nossent
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Citations
Jan 31, 2017·The American Journal of Dermatopathology·Jonathan J LeeMai P Hoang
Mar 28, 2018·The Cochrane Database of Systematic Reviews·Kurinchi Selvan GurusamyJean-François Bussières
Aug 29, 2019·Leukemia·Francesc BoschVéronique Leblond
Feb 20, 2021·British Journal of Haematology·Stephan StilgenbauerRobin Foà